Derek Archila
Stock Analyst at Wells Fargo
(3.39)
# 296
Out of 4,842 analysts
175
Total ratings
43.59%
Success rate
4.37%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SEPN Septerna | Maintains: Equal-Weight | $11 → $18 | $9.86 | +82.56% | 4 | May 16, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $30 → $26 | $17.41 | +49.34% | 11 | May 8, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $26 → $19 | $7.50 | +153.33% | 6 | May 2, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $58 → $59 | $66.04 | -10.66% | 7 | Apr 30, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $25 | $10.64 | +134.96% | 5 | Apr 9, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $80 → $91 | $61.88 | +47.06% | 5 | Apr 7, 2025 | |
| CABA Cabaletta Bio | Maintains: Equal-Weight | $6 → $3 | $1.91 | +57.07% | 10 | Apr 1, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Equal-Weight | $11 → $10 | $4.23 | +136.41% | 5 | Mar 21, 2025 | |
| QTTB Q32 Bio | Maintains: Equal-Weight | $16 → $15 | $1.89 | +693.65% | 2 | Mar 12, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $723 → $741 | $579.88 | +27.79% | 11 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $36 | $42.60 | -15.49% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $51 | $22.56 | +126.06% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $6 | $1.25 | +380.00% | 4 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $11.33 | +23.57% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $4.17 | +115.83% | 11 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $14.89 | +202.22% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $12 | $1.32 | +809.09% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $27 | $13.97 | +93.34% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $38 → $57 | $30.25 | +88.43% | 7 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $2.63 | +812.55% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $151 | $103.06 | +46.52% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.26 | +299.53% | 1 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $264 → $289 | $163.57 | +76.68% | 13 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $1.81 | +507.73% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $19.84 | +86.49% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $2.18 | +358.72% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $0.87 | +2,197.27% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.39 | +430.97% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.39 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $29.08 | +563.69% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $80.68 | -49.18% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $11.68 | +1,269.86% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $8.96 | +569.64% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.39 | +561.35% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.91 | +2,517.80% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $3.97 | +1,184.63% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $27.13 | +224.36% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $25.93 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $17.53 | - | 2 | Aug 3, 2017 |
Septerna
May 16, 2025
Maintains: Equal-Weight
Price Target: $11 → $18
Current: $9.86
Upside: +82.56%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Equal-Weight
Price Target: $30 → $26
Current: $17.41
Upside: +49.34%
Arvinas
May 2, 2025
Maintains: Overweight
Price Target: $26 → $19
Current: $7.50
Upside: +153.33%
Incyte
Apr 30, 2025
Maintains: Equal-Weight
Price Target: $58 → $59
Current: $66.04
Upside: -10.66%
Nurix Therapeutics
Apr 9, 2025
Maintains: Overweight
Price Target: $32 → $25
Current: $10.64
Upside: +134.96%
Rhythm Pharmaceuticals
Apr 7, 2025
Maintains: Overweight
Price Target: $80 → $91
Current: $61.88
Upside: +47.06%
Cabaletta Bio
Apr 1, 2025
Maintains: Equal-Weight
Price Target: $6 → $3
Current: $1.91
Upside: +57.07%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $4.23
Upside: +136.41%
Q32 Bio
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $1.89
Upside: +693.65%
argenx SE
Feb 28, 2025
Maintains: Overweight
Price Target: $723 → $741
Current: $579.88
Upside: +27.79%
Feb 24, 2025
Downgrades: Equal-Weight
Price Target: $36
Current: $42.60
Upside: -15.49%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $22.56
Upside: +126.06%
Jan 30, 2025
Maintains: Equal-Weight
Price Target: $8 → $6
Current: $1.25
Upside: +380.00%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $11.33
Upside: +23.57%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $4.17
Upside: +115.83%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $14.89
Upside: +202.22%
Dec 19, 2024
Upgrades: Overweight
Price Target: $8 → $12
Current: $1.32
Upside: +809.09%
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $27
Current: $13.97
Upside: +93.34%
Dec 2, 2024
Upgrades: Overweight
Price Target: $38 → $57
Current: $30.25
Upside: +88.43%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $2.63
Upside: +812.55%
Oct 31, 2024
Maintains: Overweight
Price Target: $153 → $151
Current: $103.06
Upside: +46.52%
Oct 4, 2024
Initiates: Overweight
Price Target: $17
Current: $4.26
Upside: +299.53%
Sep 17, 2024
Maintains: Overweight
Price Target: $264 → $289
Current: $163.57
Upside: +76.68%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $1.81
Upside: +507.73%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $19.84
Upside: +86.49%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $2.18
Upside: +358.72%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $0.87
Upside: +2,197.27%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $3.39
Upside: +430.97%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $4.39
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $29.08
Upside: +563.69%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $80.68
Upside: -49.18%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $11.68
Upside: +1,269.86%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $8.96
Upside: +569.64%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.39
Upside: +561.35%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.91
Upside: +2,517.80%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $3.97
Upside: +1,184.63%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $27.13
Upside: +224.36%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $25.93
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $17.53
Upside: -